IBB Stock UPDATES Nasdaq Biotechnology Ishares (IBB) 275.07 09/18/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 275.07 $IBB

'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.

iShares Nasdaq Biotechnology Index Falls 1.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $263.64 to a high of $268.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $268.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched  iShares Nasdaq Biotechnology Index   pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...

WIT, IBB, EROC, MPX, SEP, TUZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Wipro Ltd (NYSE:WIT), Ishares Nasdaq Biotechnology (NASDAQ:IBB), EAGLE ROCK ENERGY PARTNERS (NASDAQ:EROC), Marine Products Corp (NYSE:MPX), Spectra Energy Partners LP (NYSE:SEP), PimCo 1 3 Year Us Treasury Index Fund (NYSE:TUZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

After Yesterday's Rally of 1.85% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 10, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 1.85%
Comtex SmarTrend(R) - Wed Sep 10, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading